Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of R-OKY-034F in refractory, unresectable pancreatic cancer
jRCT2051190003Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R-OKY-034F in pancreatic adenocarcinoma (PDAC), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety - dose-limiting toxicity (DLT), Safety - maximum tolerated dose (MTD) and 1 more. Started Mar 2019; status: completed.
02
Drugs
R-OKY-034F
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2051190003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190003.